Atea Pharmaceuticals, Inc. Cash and Cash Equivalents
Atea Pharmaceuticals, Inc. (AVIR) had Cash and Cash Equivalents of $76.55 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-12
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $76.55M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $79.32M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $95.71M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $77.34M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $76.55M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $79.32M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $95.71M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $77.34M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $87.72M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $119.39M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $64.70M 10-K · filed 2026-03-05 |
| 2024-09-30 | $98.46M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $243.39M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $160.91M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $143.82M 10-K · filed 2025-03-06 |
| 2023-09-30 | $137.89M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $213.70M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $183.25M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $188.46M 10-K · filed 2024-02-28 |
| 2022-09-30 | $176.41M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $684.48M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $705.54M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $764.38M 10-K · filed 2023-02-28 |
| 2021-09-30 | $839.66M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $816.46M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $833.75M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $850.12M 10-K · filed 2023-02-28 |
| 2020-09-30 | $105.38M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $115.79M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $17.15M 10-Q · filed 2021-05-13 |
| 2019-12-31 | $21.66M 10-K · filed 2022-02-28 |
| 2019-09-30 | $25.60M 10-Q · filed 2020-12-10 |
| 2018-12-31 | $34.49M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |